Abstract
Histological haematoxylin and eosin–stained (H&E) tissue sections are used as the gold standard for pathologic detection of cancer, tumour margin detection, and disease diagnosis1. Producing H&E sections, however, is invasive and time-consuming. Non-invasive optical imaging modalities, such as optical coherence tomography (OCT), permit label-free, micron-scale 3D imaging of biological tissue microstructure with significant depth (up to 1mm) and large fields-of-view2, but are difficult to interpret and correlate with clinical ground truth without specialized training3. Here we introduce the concept of a virtual biopsy, using generative neural networks to synthesize virtual H&E sections from OCT images. To do so we have developed a novel technique, “optical barcoding”, which has allowed us to repeatedly extract the 2D OCT slice from a 3D OCT volume that corresponds to a given H&E tissue section, with very high alignment precision down to 25 microns. Using 1,005 prospectively collected human skin sections from Mohs surgery operations of 71 patients, we constructed the largest dataset of H&E images and their corresponding precisely aligned OCT images, and trained a conditional generative adversarial network4 on these image pairs. Our results demonstrate the ability to use OCT images to generate high-fidelity virtual H&E sections and entire 3D H&E volumes. Applying this trained neural network to in vivo OCT images should enable physicians to readily incorporate OCT imaging into their clinical practice, reducing the number of unnecessary biopsy procedures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by grants from the United States Air Force (FA9550-15-1-0007), the National Institutes of Health (NIH DP50D012179, K23CA211793), the National Science Foundation (NSF 1438340), the Damon Runyon Cancer Research Foundation (DFS# 06-13), Claire Giannini Fund, the Susan G. Komen Breast Cancer Foundation (SAB15-00003), the Mary Kay Foundation (017-14), the Skippy Frank Foundation, the Donald E. and Delia B. Baxter Foundation, a seed grant from the Center for Cancer Nanotechnology Excellence and Translation (CCNE-T; NIH-NCI U54CA151459), and the Stanford Bio-X Interdisciplinary Initiative Seed Grant (IIP6-43). Y.W. is grateful for a Stanford Bowes Bio-X Graduate Fellowship, Stanford Biophysics Program training grant (T32GM-08294). I.T. is grateful for NSF graduate fellowship. A.D.Z. is a Chan Zuckerberg Biohub investigator and a Pew-Stewart Scholar for Cancer Research supported by The Pew Charitable Trusts and The Alexander and Margaret Stewart Trust. K.Y.S. is the D. G. Mitch Mitchell Clinical Investigator supported by the Damon Runyon Cancer Research Foundation (CI-104-19).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stanford IRB-24307
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request
